MA
BNTC icon

MYDA Advisors’s Benitec Biopharma BNTC Stock Holding History

MYDA Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Buy
250,000
+25,000
+11% +$297K 0.5% 57
2026
Q1 		$2.4M Hold
225,000
– – 0.39% 63
2025
Q4 		$3.03M Buy
225,000
+155,000
+221% +$2.14M 0.58% 44
2025
Q3 		$982K Buy
70,000
+7,884
+13% +$101K 0.21% 96
2025
Q2 		$727K Buy
62,116
+10,116
+19% +$142K 0.13% 104
2025
Q1 		$677K Buy
52,000
+2,000
+4% +$24.2K 0.12% 104
2024
Q4 		$632K Buy
+50,000
New +$540K 0.16% 83

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

MYDA Advisors's BNTC Position: Q2 2026 in Review

MYDA Advisors increased its Benitec Biopharma (BNTC) stake by 11% in Q2 2026, buying an estimated $297K and bringing the position to 250,000 shares worth $3.35M. The position accounts for 0.5% of the portfolio, ranked #57.

MYDA Advisors first reported a position in BNTC in Q4 2024 and has held it in 7 quarters since. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • MYDA Advisors held 250,000 shares of Benitec Biopharma worth $3.35M as of Q2 2026.
  • MYDA Advisors bought 25,000 Benitec Biopharma shares in Q2 2026, an estimated $297K.
  • Benitec Biopharma made up 0.5% of MYDA Advisors's portfolio in Q2 2026, its #57 holding.
  • MYDA Advisors first reported a position in Benitec Biopharma in Q4 2024 and has held it in 7 quarters since.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on MYDA Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.